Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

vTv Therapeutics Q3 2026 Results: Net Loss of $11.6M, Loss Widens

vTv Therapeutics reported a significantly reduced net loss of $0.5 million for the nine months ended September 30, 2026, compared to $23.9 million in the prior year, primarily due to $36.8 million in revenue recognized from contract liabilities. However, the company experienced an operating loss of $12.4 million for the third quarter as research and development expenses increased to support ongoing clinical programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Profit before tax-11.6-10.3
Net income-11.6-8.7

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: VTVT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

vTv Therapeutics Inc.: key numbers

Share price
$17.69Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from vTv Therapeutics Inc.

All →
4:23 PM ET 8-K
Financial Results

vTv Therapeutics Financial Results

vTv Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting the completion of enrollment for its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. The company also announced that the FDA granted Orphan Drug Designation to HPPD for sickle cell disease and expects its current cash position to fund operations through the mid-2027 CATT1 topline data readout.

“Completing enrollment in the Phase 3 CATT1 trial is a significant milestone for vTv, and we look forward to reporting topline results in mid 2027.”

Paul Sekhri, Chairman, President and Chief Executive Officer

“The FDA recently granted Orphan Drug Designation for HPPD, which has shown promising activity in preclinical models of sickle cell disease. This designation strengthens our ability to advance partnering discussions for this program and provides another opportunity to create value for shareholders.”

Paul Sekhri, Chairman, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.